Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With HoFH and HeFH, CVD, or at High Risk for CVD, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction

Next Previous
Trial Profile

Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With HoFH and HeFH, CVD, or at High Risk for CVD, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lerodalcibep (Primary) ; Bempedoic acid; Bezafibrate; Bile acids and salts; Ezetimibe; Fenofibrate; HMG-CoA reductase inhibitors; Niacin; Omega-3-fatty-acid
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Adverse reactions; Registrational
  • Acronyms LIBerate-007; LIBerate-OLE
  • Sponsors LIB Therapeutics

Most Recent Events

  • 30 Mar 2026 Results of Long-term Efficacy and Safety of Lerodalcibep from oral poster presentation were presented at the March 28-30, 2026 American College of Cardiology meeting in New Orleans, according to LIB Therapeutics Media Release.
  • 30 Mar 2026 Results presented in the LIB Therapeutics Media Release.
  • 24 Mar 2026 According to a Everest Medicines media release, results from this study will be presented on Saturday Mar 28 2026 3:30 PM - 4:30 PM at 2026 American College of Cardiology Annual Scientific Session (ACC.26).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top